Odyssey Therapeutics Appoints Dennis Dean as EVP, Head of Non-Clinical Development
Odyssey Therapeutics, a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, appointed Dennis Dean, Ph.D., as Executive Vice President and Head of Non-Clinical Development on November 11, 20251379.
Dr. Dean will oversee all preclinical research and development, including toxicology, drug metabolism and pharmacokinetics (DMPK), chemistry, manufacturing and controls (CMC), and program management1.
He will collaborate with Discovery Research, Research Operations, and Clinical Development to ensure non-clinical programs are scientifically rigorous and regulatory compliant1.
Dr. Dean brings over 25 years’ experience from roles at Third Harmonic Bio, IFM Therapeutics, Vertex Pharmaceuticals, and Merck Research Laboratories, contributing to multiple successful drug program advancements and acquisitions1.
His expertise spans toxicology, pharmacology, translational sciences, and advancing drug candidates from discovery through Investigational New Drug (IND) filings and into clinical trials1.
Dean holds a Ph.D. in medicinal chemistry from SUNY Buffalo and completed postdoctoral research at Emory University; he has co-authored more than 90 publications1.
Odyssey Therapeutics recently raised a $213 million Series D round to advance its portfolio, including continued development of its autoimmune disease programs7.
Sources:
1. https://odysseytx.com/odyssey-therapeutics-appoints-dennis-dean-ph-d-as-executive-vice-president-head-of-non-clinical-development/
7. https://www.businesswire.com/news/home/20250910622822/en/Odyssey-Therapeutics-Announces-Oversubscribed-$213-Million-Series-D-Financing-to-Advance-Clinical-Pipeline-for-Autoimmune-Diseases